Mouse strains for prostate tumorigenesis based on genes altered in human prostate cancer

W. C. Powell, Robert Cardiff, M. B. Cohen, G. J. Miller, P. Roy-Burman

Research output: Contribution to journalReview article

22 Citations (Scopus)

Abstract

Animal models of prostate cancer have been limited in number and in relevance to the human disease. With the advancement of transgenic and knockout technologies, combined with tissue specific promoters and tissue-specific gene ablation, a new generation of mouse models has emerged. This review will discuss various animal models and their inherent strengths and weaknesses. A primary emphasis is placed on mouse models that have been designed on the basis of genetic alterations that are frequently found in human prostate cancer. These models display slow, temporal development of increasingly severe histopathologic lesions, which are remarkably restricted to the prostate gland, a property similar to the ageing related progression of this disease in humans. The preneoplastic lesions, akin to what is considered as prostatic intraepithelial neoplasia, are consistent major phenotypes in the models, and, therefore, are discussed for histopathologic criteria that may distinguish their progressions or grades. Finally, considering that prostate cancer is a complex multifocal disease, which is likely to require multiple genetic/epigenetic alterations, many of these models have already been intercrossed to derive mice with compound genetic alterations. It is predicted that these and subsequent compound mutant mice should represent "natural" animal models for investigating the mechanism of development of human prostate diseases, as well as, for preclinical models for testing therapeutics.

Original languageEnglish (US)
Pages (from-to)263-279
Number of pages17
JournalCurrent Drug Targets
Volume4
Issue number3
DOIs
StatePublished - Apr 1 2003

Fingerprint

Prostate
Prostatic Neoplasms
Carcinogenesis
Genes
Animal Models
Prostatic Intraepithelial Neoplasia
Animals
Human Development
Epigenomics
Disease Progression
Technology
Phenotype
Tissue
Ablation
Aging of materials
Therapeutics
Testing

Keywords

  • Animal model
  • Growth factors
  • Prostate cancer
  • Prostate epithelium-specific gene inactivation
  • Retinoid receptors
  • Tissue-specific promoters
  • Tumor suppressors

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

Mouse strains for prostate tumorigenesis based on genes altered in human prostate cancer. / Powell, W. C.; Cardiff, Robert; Cohen, M. B.; Miller, G. J.; Roy-Burman, P.

In: Current Drug Targets, Vol. 4, No. 3, 01.04.2003, p. 263-279.

Research output: Contribution to journalReview article

Powell, W. C. ; Cardiff, Robert ; Cohen, M. B. ; Miller, G. J. ; Roy-Burman, P. / Mouse strains for prostate tumorigenesis based on genes altered in human prostate cancer. In: Current Drug Targets. 2003 ; Vol. 4, No. 3. pp. 263-279.
@article{99d7f8508aa24fdb86dc720ec5f1b5cd,
title = "Mouse strains for prostate tumorigenesis based on genes altered in human prostate cancer",
abstract = "Animal models of prostate cancer have been limited in number and in relevance to the human disease. With the advancement of transgenic and knockout technologies, combined with tissue specific promoters and tissue-specific gene ablation, a new generation of mouse models has emerged. This review will discuss various animal models and their inherent strengths and weaknesses. A primary emphasis is placed on mouse models that have been designed on the basis of genetic alterations that are frequently found in human prostate cancer. These models display slow, temporal development of increasingly severe histopathologic lesions, which are remarkably restricted to the prostate gland, a property similar to the ageing related progression of this disease in humans. The preneoplastic lesions, akin to what is considered as prostatic intraepithelial neoplasia, are consistent major phenotypes in the models, and, therefore, are discussed for histopathologic criteria that may distinguish their progressions or grades. Finally, considering that prostate cancer is a complex multifocal disease, which is likely to require multiple genetic/epigenetic alterations, many of these models have already been intercrossed to derive mice with compound genetic alterations. It is predicted that these and subsequent compound mutant mice should represent {"}natural{"} animal models for investigating the mechanism of development of human prostate diseases, as well as, for preclinical models for testing therapeutics.",
keywords = "Animal model, Growth factors, Prostate cancer, Prostate epithelium-specific gene inactivation, Retinoid receptors, Tissue-specific promoters, Tumor suppressors",
author = "Powell, {W. C.} and Robert Cardiff and Cohen, {M. B.} and Miller, {G. J.} and P. Roy-Burman",
year = "2003",
month = "4",
day = "1",
doi = "10.2174/1389450033491145",
language = "English (US)",
volume = "4",
pages = "263--279",
journal = "Current Drug Targets",
issn = "1389-4501",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

TY - JOUR

T1 - Mouse strains for prostate tumorigenesis based on genes altered in human prostate cancer

AU - Powell, W. C.

AU - Cardiff, Robert

AU - Cohen, M. B.

AU - Miller, G. J.

AU - Roy-Burman, P.

PY - 2003/4/1

Y1 - 2003/4/1

N2 - Animal models of prostate cancer have been limited in number and in relevance to the human disease. With the advancement of transgenic and knockout technologies, combined with tissue specific promoters and tissue-specific gene ablation, a new generation of mouse models has emerged. This review will discuss various animal models and their inherent strengths and weaknesses. A primary emphasis is placed on mouse models that have been designed on the basis of genetic alterations that are frequently found in human prostate cancer. These models display slow, temporal development of increasingly severe histopathologic lesions, which are remarkably restricted to the prostate gland, a property similar to the ageing related progression of this disease in humans. The preneoplastic lesions, akin to what is considered as prostatic intraepithelial neoplasia, are consistent major phenotypes in the models, and, therefore, are discussed for histopathologic criteria that may distinguish their progressions or grades. Finally, considering that prostate cancer is a complex multifocal disease, which is likely to require multiple genetic/epigenetic alterations, many of these models have already been intercrossed to derive mice with compound genetic alterations. It is predicted that these and subsequent compound mutant mice should represent "natural" animal models for investigating the mechanism of development of human prostate diseases, as well as, for preclinical models for testing therapeutics.

AB - Animal models of prostate cancer have been limited in number and in relevance to the human disease. With the advancement of transgenic and knockout technologies, combined with tissue specific promoters and tissue-specific gene ablation, a new generation of mouse models has emerged. This review will discuss various animal models and their inherent strengths and weaknesses. A primary emphasis is placed on mouse models that have been designed on the basis of genetic alterations that are frequently found in human prostate cancer. These models display slow, temporal development of increasingly severe histopathologic lesions, which are remarkably restricted to the prostate gland, a property similar to the ageing related progression of this disease in humans. The preneoplastic lesions, akin to what is considered as prostatic intraepithelial neoplasia, are consistent major phenotypes in the models, and, therefore, are discussed for histopathologic criteria that may distinguish their progressions or grades. Finally, considering that prostate cancer is a complex multifocal disease, which is likely to require multiple genetic/epigenetic alterations, many of these models have already been intercrossed to derive mice with compound genetic alterations. It is predicted that these and subsequent compound mutant mice should represent "natural" animal models for investigating the mechanism of development of human prostate diseases, as well as, for preclinical models for testing therapeutics.

KW - Animal model

KW - Growth factors

KW - Prostate cancer

KW - Prostate epithelium-specific gene inactivation

KW - Retinoid receptors

KW - Tissue-specific promoters

KW - Tumor suppressors

UR - http://www.scopus.com/inward/record.url?scp=0345268686&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0345268686&partnerID=8YFLogxK

U2 - 10.2174/1389450033491145

DO - 10.2174/1389450033491145

M3 - Review article

VL - 4

SP - 263

EP - 279

JO - Current Drug Targets

JF - Current Drug Targets

SN - 1389-4501

IS - 3

ER -